Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- IMpassion132
Clinical trial of atezolizumab plus chemotherapy compared with chemotherapy alone for patients with recurrent triple-negative breast cancer (IMpassion132)
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)
Cancer Breast Cancer Triple Negative Breast Neoplasms Triple Negative Breast Cancer
- Results
-
Download -
Study results
LPS MO39193 IMpassion132 Interim Results October 2024 English
(PDF, 0.4 MB)
LPS MO39193 IMpassion132 Final Results July 2025 English
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Argentina Spanish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Serbian Cyrillic
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Polish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Montenegrin
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Kazakh
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Italian
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 German
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Costa Rica Spanish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Brazil Portuguese
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 UK English
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Turkish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Portugal Portuguese
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Morocco French
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Korean
(PDF, 1.1 MB)
LPS MO39193 IMpassion132 Final Results July 2025 France French
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Finnish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Chile Spanish
(PDF, 0.9 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Bosnian Cyrillic
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Spain Spanish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Spain Galician
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Spain Catalan
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Singapore Malay
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Singapore Chinese
(PDF, 1.1 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Russian
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Panama Spanish
(PDF, 0.9 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Mexico Spanish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Hungarian
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Cuba Spanish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Chinese
(PDF, 1.1 MB)
LPS MO39193 IMpassion132 Final Results July 2025 South Africa Zulu
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 South Africa Xhosa
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 South Africa Northern Sotho
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 South Africa English
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 South Africa Afrikaans
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 Peru Spanish
(PDF, 1.0 MB)
LPS MO39193 IMpassion132 Final Results July 2025 USA Spanish
(PDF, 0.9 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com